OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
OWLT$5.4059

Owlet Inc

Advanced Medical Equipment & TechnologyVerified

Owlet Inc operates with a negative equity position of -$20.83 million and a total debt of $11.85 million, indicating a leveraged capital structure. The company's liquidity position is constrained, with $15.36 million in cash and equivalents, but a current ratio of 1.01 suggests limited short-term liquidity buffer. The negative return on equity of 5.51% and a negative return on assets of -2.5% highlight the company's underperformance in generating returns from its equity and asset base. The company's operating income of -$2.24 million and net income of -$1.15 million indicate ongoing operational losses. These figures are below the industry median for profitability metrics, suggesting that Owlet Inc is not performing as well as its peers in terms of generating profit. The gross profit margin of 49.5% is relatively high, but this is offset by significant operating expenses that erode profitability. Owlet Inc's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases the company's exposure to market-specific risks and limits its ability to offset losses in one area with gains in another. The company's revenue of $20.70 million is modest compared to industry leaders, and there is no indication of significant geographic expansion. The company's growth trajectory is uncertain, with no disclosed revenue growth in the current fiscal year. The negative operating cash flow of -$6.72 million and free cash flow of -$2.60 million indicate that the company is not generating sufficient cash to fund operations or growth initiatives. The capital expenditure of -$74,000 suggests minimal investment in long-term assets, which may limit future growth potential. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative equity and high debt-to-equity ratio of -0.57 suggest potential financial instability. The dilution potential is low, but the company's negative net income and operating cash flow could necessitate future equity raises, which may dilute existing shareholders. Recent events include analyst estimates indicating a strong buy recommendation with a mean price target of $14.25 and a median price target of $14.50. These estimates suggest that analysts have a positive outlook on the company's future performance, despite its current financial challenges.

30-day price · OWLT+0.30 (+5.9%)
Low$4.19High$6.35Close$5.40As of14 May, 00:00 UTC
Profile
CompanyOwlet Inc
TickerOWLT.K
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
AI analysis

Business. Owlet Inc is a provider of advanced medical equipment and technology, specializing in wearable health monitoring devices for infants and children.

Classification. Owlet Inc is classified under the Healthcare sector, specifically in the Advanced Medical Equipment & Technology industry, with a confidence level of 0.92.

Owlet Inc operates with a negative equity position of -$20.83 million and a total debt of $11.85 million, indicating a leveraged capital structure. The company's liquidity position is constrained, with $15.36 million in cash and equivalents, but a current ratio of 1.01 suggests limited short-term liquidity buffer. The negative return on equity of 5.51% and a negative return on assets of -2.5% highlight the company's underperformance in generating returns from its equity and asset base. The company's operating income of -$2.24 million and net income of -$1.15 million indicate ongoing operational losses. These figures are below the industry median for profitability metrics, suggesting that Owlet Inc is not performing as well as its peers in terms of generating profit. The gross profit margin of 49.5% is relatively high, but this is offset by significant operating expenses that erode profitability. Owlet Inc's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases the company's exposure to market-specific risks and limits its ability to offset losses in one area with gains in another. The company's revenue of $20.70 million is modest compared to industry leaders, and there is no indication of significant geographic expansion. The company's growth trajectory is uncertain, with no disclosed revenue growth in the current fiscal year. The negative operating cash flow of -$6.72 million and free cash flow of -$2.60 million indicate that the company is not generating sufficient cash to fund operations or growth initiatives. The capital expenditure of -$74,000 suggests minimal investment in long-term assets, which may limit future growth potential. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative equity and high debt-to-equity ratio of -0.57 suggest potential financial instability. The dilution potential is low, but the company's negative net income and operating cash flow could necessitate future equity raises, which may dilute existing shareholders. Recent events include analyst estimates indicating a strong buy recommendation with a mean price target of $14.25 and a median price target of $14.50. These estimates suggest that analysts have a positive outlook on the company's future performance, despite its current financial challenges.
Key takeaways
  • Owlet Inc is operating at a loss with negative equity and high debt, indicating financial distress.
  • The company's profitability metrics are below industry medians, suggesting underperformance relative to peers.
  • Owlet Inc's revenue is concentrated in a single segment with no geographic diversification, increasing business risk.
  • Analysts have a positive outlook on the company, with a mean price target significantly higher than the current market price.
  • The company's liquidity position is weak, with limited cash reserves and a current ratio near 1.0.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$20.7M
Gross profit$10.3M
Operating income-$2.2M
Net income-$1.1M
R&D
SG&A
D&A
SBC
Operating cash flow-$6.7M
CapEx-$74.0k
Free cash flow-$2.6M
Total assets$45.9M
Total liabilities$66.7M
Total equity-$20.8M
Cash & equivalents$15.4M
Long-term debt$11.8M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$75.8M-$53.7M-$71.7M-$72.6M
FY-3$69.2M-$84.6M-$79.3M-$79.5M
FY-2$54.0M-$28.6M-$32.9M-$36.7M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
PeriodAssetsEquityCashDebt
FY-4$140.0M$55.2M$95.1M
FY-3$58.1M-$10.6M$11.2M
FY-2$44.1M-$29.7M$16.6M
PeriodOCFCapExFCFSBC
FY-4-$40.6M-$2.0M-$72.6M
FY-3-$81.4M-$1.6M-$79.5M
FY-2-$23.5M-$59.0k-$36.7M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$20.7M-$2.2M-$1.1M-$2.6M
FQ-1$26.6M-$4.9M-$9.2M-$10.4M
FQ0$22.5M-$3.3M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$45.9M-$20.8M$15.4M
FQ-1$85.6M$35.5M$35.5M
FQ0$21.0M$35.5M
PeriodOCFCapExFCFSBC
FQ-7-$6.7M-$74.0k-$2.6M
FQ-1-$10.8M-$943.0k-$10.4M
FQ0-$5.0M-$415.0k
Valuation
Market price$5.40
Market cap$156.6M
Enterprise value$153.1M
P/E
Reported non-GAAP P/E
EV/Revenue7.4
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book-$20.8M
Net cash$3.5M
Current ratio1.0
Debt/Equity-0.6
ROA-2.5%
ROE5.5%
Cash conversion5.9%
CapEx/Revenue-0.4%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Advanced Medical Equipment & Technology · cohort 109 companies
MetricOWLTActivity
Op margin-10.8%-19.9% medp25 -150.5% · p75 8.7%above median
Net margin-5.5%-18.4% medp25 -146.8% · p75 8.0%above median
Gross margin49.5%49.9% medp25 36.2% · p75 66.3%below median
R&D / revenue6.2% medp25 4.7% · p75 12.0%
CapEx / revenue-0.4%-3.5% medp25 -7.8% · p75 -1.4%top quartile
Debt / equity-57.0%14.5% medp25 0.9% · p75 54.2%bottom quartile
Observations
IR observations
Mean price target14.25 USD
Median price target14.50 USD
High price target15.00 USD
Low price target13.00 USD
Mean recommendation1.80 (1=strong buy, 5=strong sell)
Strong-buy count1.00
Buy count4.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate-0.25 USD
Last actual EPS-0.11 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-16 14:20 UTC#99126822
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 21:43 UTCJob: 800fabd6